Felicis
Listed as “Granza Bio”
- First observed:
- 31 Oct 2026
- Investment announced:
- Date not recorded
Granza Bio
Granza Bio uses the discovery of immune-system attack particles.
- Tracked VC backers
- 1
RiseFinder summary
Granza Bio uses the discovery of immune-system attack particles. The company says these particles are released from cytotoxic immune cells. It describes its focus as target-specific medicines.
- Company website ↗ · Checked
Tracking coverage and points
Tracking coverage
Some source history is available; coverage remains limited.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Awaiting data
- No verified dated source evidence recorded.
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Awaiting data
- Exit news coverage has not started.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
Publicly documented VC backing
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Dated public activity
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.